BioAge Labs Statistics

Total Valuation

BioAge Labs has a market cap or net worth of $184.26 million. The enterprise value is -$140.00 million.

Market Cap	184.26M
Enterprise Value	-140.00M

Important Dates

The next estimated earnings date is Saturday, February 15, 2025, before market open.

Earnings Date	Feb 15, 2025
Ex-Dividend Date	n/a

Share Statistics

BioAge Labs has 35.85 million shares outstanding. The number of shares has increased by 28.09% in one year.

Current Share Class	35.85M
Shares Outstanding	35.85M
Shares Change (YoY)	+28.09%
Shares Change (QoQ)	+104.24%
Owned by Insiders (%)	3.63%
Owned by Institutions (%)	47.55%
Float	24.24M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.56
P/TBV Ratio	0.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.63, with a Debt / Equity ratio of 0.03.

Current Ratio	17.63
Quick Ratio	17.53
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-14.42

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.27M
Employee Count	56
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	11.76
200-Day Moving Average	n/a
Relative Strength Index (RSI)	33.46
Average Volume (20 Days)	982,871

Short Selling Information

The latest short interest is 2.06 million, so 5.74% of the outstanding shares have been sold short.

Short Interest	2.06M
Short Previous Month	1.35M
Short % of Shares Out	5.74%
Short % of Float	8.49%
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-66.43M
Pretax Income	-62.16M
Net Income	-70.94M
EBITDA	-66.27M
EBIT	-66.43M
Earnings Per Share (EPS)	-$33.13

Full Income Statement

Balance Sheet

The company has $334.47 million in cash and $10.21 million in debt, giving a net cash position of $324.26 million or $9.05 per share.

Cash & Cash Equivalents	334.47M
Total Debt	10.21M
Net Cash	324.26M
Net Cash Per Share	$9.05
Equity (Book Value)	313.75M
Book Value Per Share	9.17
Working Capital	317.39M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$54.89 million and capital expenditures -$340,000, giving a free cash flow of -$55.23 million.

Operating Cash Flow	-54.89M
Capital Expenditures	-340,000
Free Cash Flow	-55.23M
FCF Per Share	-$1.54

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BioAge Labs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-28.09%
Shareholder Yield	-28.09%
Earnings Yield	-38.50%
FCF Yield	-29.97%

Analyst Forecast

The average price target for BioAge Labs is $18.00, which is 250.20% higher than the current price. The consensus rating is "Hold".

Price Target	$18.00
Price Target Difference	250.20%
Analyst Consensus	Hold
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2